Eosinophilic granulomatosis with polyangiitis

References

• Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27(2):277–301.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Arthritis Rheum. 1994;37(2):187–192.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2012;65(1):1–11.
   Web of Science ®Google Scholar
• Sinico RA, Toma LD, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926–2935.
   PubMed Web of Science ®Google Scholar
• Moiseev S, Bossuyt X, Arimura Y, et al. International consensus on antineutrophil cytoplasm antibodies testing in eosinophilic granulomatosis with polyangiitis. Am J Respir Crit Care Med. 2020;202(10):1360–1372.
   Web of Science ®Google Scholar
• Romero-Gomez C, Aguilar-Garcia JA, Garcia-de-Lucas MD, et al. Epidemiological study of primary systemic vasculitides among adults in southern Spain and review of the main epidemiological studies. Clin Exp Rheumatol. 2015;33(2 Suppl 89):11–18.
   PubMed Web of Science ®Google Scholar
• Watts RA, Lane S, Scott DG. What is known about the epidemiology of the vasculitides? Best Pract Res Clin Rheumatol. 2005;19(2):191–207.
   PubMed Web of Science ®Google Scholar
• Gibelin A, Maldini C, Mahr A. Epidemiology and etiology of Wegener granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and Goodpasture syndrome: vasculitides with frequent lung involvement. Semin Respir Crit Care Med. 2011;32(3):264–273.
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology. 2011;50(10):1916–1920.
   PubMed Web of Science ®Google Scholar
• Watts RA, Lane SE, Bentham G, et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000;43(2):414–419.
   PubMed Web of Science ®Google Scholar
• Jakes RW, Kwon N, Nordstrom B, et al. Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis. Clin Rheumatol. 2021;40(12):4829–4836.
   PubMed Web of Science ®Google Scholar
• Doubelt I, Cuthbertson D, Carette S, et al. Clinical manifestations and long-term outcomes of eosinophilic granulomatosis with polyangiitis in North America. ACR Open Rheumatol. 2021;3(6):404–412.
   PubMedGoogle Scholar
• Fagni F, Bello F, Emmi G. Eosinophilic granulomatosis with polyangiitis: dissecting the pathophysiology. Front Med. 2021;8:1–10.
   Web of Science ®Google Scholar
• Gioffredi A, Maritati F, Oliva E, et al. Eosinophilic granulomatosis with polyangiitis: an overview. Front Immunol. 2014;5:549.
   PubMed Web of Science ®Google Scholar
• Nishi R, Koike H, Ohyama K, et al. Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA. Neurology. 2020;94(16):e1726–e1737 .
   PubMed Web of Science ®Google Scholar
• Koike H, Nishi R, Furukawa S, et al. In vivo visualization of eosinophil secretion in eosinophilic granulomatosis with polyangiitis: an ultrastructural study. Allergol Int. 2022;12:S1323–8930 .
   Google Scholar
• Lyons PA, Peters JE, Alberici F, et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun. 2019;10(1):5120.
   PubMed Web of Science ®Google Scholar
• Cottin V, Bel E, Bottero P, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev. 2017;16(1):1–9.
   PubMed Web of Science ®Google Scholar
• Weller PF, Plaut M, Taggart V, et al. The relationship of asthma therapy and Churg Strauss syndrome. J Allergy Clin Immunol. 2001;108(2):175–183.
   PubMedGoogle Scholar
• Tuggey JM, Hosker HSR. Churg-Strauss syndrome associated with montelukast therapy. Thorax. 2000;55(9):805–806.
   PubMed Web of Science ®Google Scholar
• Hauser T, Mahr A, Metzler C, et al. The leukotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax. 2008;63(8):677–682.
   PubMed Web of Science ®Google Scholar
• Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplastic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115(4):284–290.
   PubMed Web of Science ®Google Scholar
• Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg580 Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72(6):1011–1017.
   PubMed Web of Science ®Google Scholar
• Samson M, Puéchal X, Devilliers H, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60–69.
   PubMed Web of Science ®Google Scholar
• Durel C, Berthiller J, Caboni S, et al. Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Arthritis Care Res. 2016;68(3):374–387.
   PubMed Web of Science ®Google Scholar
• Saku A, Furuta S, Hiraguri M, et al. Longterm outcomes of 188 Japanese patients with eosinophilic granulomatosis with polyangiitis. J Rheumatol. 2018;45(8):1159–1166.
   PubMed Web of Science ®Google Scholar
• Lanham JG, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984;63(2):65–81.
   PubMed Web of Science ®Google Scholar
• Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French vasculitis study group cohort. Arthritis Rheum. 2013;65(1):270–281.
   PubMed Web of Science ®Google Scholar
• Sada K, Amano K, Uehara R, et al. A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan. Mod Rheumatol. 2014;24(4):640–644.
   PubMed Web of Science ®Google Scholar
• Bacciu A, Bacciu S, Mercante G, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol. 2006;126(5):503–509. DOI:10.1080/00016480500437435.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78(1):26–37.
   PubMed Web of Science ®Google Scholar
• Berti A, Volcheck GW, Cornec D, et al. Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. Respir Med. 2018;142:66–72.
   PubMed Web of Science ®Google Scholar
• Kim M, Sohn K, Song W, et al. Clinical features and prognostic factors of Churg-Strauss syndrome. Korean J Intern Med. 2014;29(1):85–95. criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1094- 1100122-1128.
   PubMed Web of Science ®Google Scholar
• Neumann T, Manger B, Schmid M, et al. Cardiac involvement in ChurgStrauss syndrome: impact of endomyocarditis. Medicine (Baltimore). 2009;88(4):236–243.
   PubMed Web of Science ®Google Scholar
• Masi AT, Hunder CG, Lie JT, et al. The American college of rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094–1100. DOI:10.1002/art.1780330806.
   PubMed Web of Science ®Google Scholar
• Valent P, Gleich GJ, Reiter A, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol. 2012;5(2):157–176.
   PubMed Web of Science ®Google Scholar
• Feragalli B, Mantini C, Sperandeo M, et al. The lung in systemic vasculitis: radiological patterns and differential diagnosis. Br J Radiol. 2016;89(1061):20150992.
   PubMed Web of Science ®Google Scholar
• Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143(9):632–638.
   PubMed Web of Science ®Google Scholar
• Hazebroek MR, Kemna MJ, Schalla S, et al. Prevalence and prognostic relevance of cardiac involvement in anca-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. Int J Cardiol. 2015;199:170–179.
   PubMed Web of Science ®Google Scholar
• Szczeklik W, Miszalski-Jamka T, Mastalerz L, et al. Multimodality assessment of cardiac involvement in Churg-Strauss syndrome patients in clinical remission. Circ J. 2011;75(3):649–655.
   PubMed Web of Science ®Google Scholar
• Dennert RM, van Paassen P, Schalla S, et al. Cardiac Involvement in Churg-Strauss syndrome. Arthritis Rheum. 2010;62(2):627–634.
   PubMed Web of Science ®Google Scholar
• Wassmuth R, Gobel U, Natusch A. Cardiovascular magnetic resonance imaging detects cardiac involvement in churg-strauss syndrome. J Card Fail. 2008;14(10):856–860.
   PubMed Web of Science ®Google Scholar
• Marmursztejn J, Guillevin L, Trebossen R. Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. Rheumatology. 2013;52(4):642–650.
   PubMed Web of Science ®Google Scholar
• Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor prognosis factors: a multicenter, prospective, randomized, open-label study of seventy497 two patients. Arthritis Rheum. 2008;58(2):586–594.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Quemeneur T, Ninet J, et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheum. 2015;67(4):1117–1127.
   PubMed Web of Science ®Google Scholar
• Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007;57(4):1556–1563.
   Web of Science ®Google Scholar
• Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore). 1996;75(1):17–28.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Seror R, et al. The five-Factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19–27.
   PubMed Web of Science ®Google Scholar
• Chung SA, Langford CA, Maz M, et al. American college of rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2021;73(8):1366–1383.
   PubMed Web of Science ®Google Scholar
• Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis Churg-Strauss) (EGPA) consensus task force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545–553.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 2016;75(2):396–401.
   PubMed Web of Science ®Google Scholar
• Theil J, Troilo A, Salzer U, et al. Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-Month follow-Up analysis. J Allergy Clin Immunol Pract. 2017;5(6):1556–1563.
   PubMed Web of Science ®Google Scholar
• Teixeira V, Mohammad AJ, Jones RB, et al. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019;5(1):e000905.
   PubMed Web of Science ®Google Scholar
• Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 2001;44(3):666–675.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921–1932.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Nencini F, Bormioli S, et al. Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis. Allergy Asthma Immunol Res. 2020;12(5):885–893.
   PubMed Web of Science ®Google Scholar
• Ríos-Garcés R, Prieto-González S, Hernández-Rodríguez J, et al. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis. Eur J Intern Med. 2022;95:61–66.
   PubMed Web of Science ®Google Scholar
• Manka LA, Guntur VP, Denson JL, et al. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann Allergy Asthma Immunol. 2021;126(6):696–701.
   PubMed Web of Science ®Google Scholar
• Guntur PV, Manka LA, Denson JL, et al. Benralizumab as a steroid-Sparing treatment option in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2021;9(3):1186–1193.
   PubMed Web of Science ®Google Scholar
• Maritati F, Alberici F, Oliva E, et al. Methotrexate versus cyclophosphamide for remission maintenance in anca-associated vasculitis: a randomized trial. PLuS One. 2017;12(10):e0185880​.
   PubMed Web of Science ®Google Scholar
• Metzler C, Hellmich B, Gause A. Churg-Strauss syndrome – successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ration during maintenance treatment. Clin Exp Rheumatol. 2004;22(6 Suppl 36):S52–61.
   PubMed Web of Science ®Google Scholar
• Puéchal X, Pagnoux C, Baron G, et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial. Arthritis Rheum. 2017;69(11):2175–2186.
   PubMed Web of Science ®Google Scholar
• Herrmann K, Gross WL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2012;30(1 Suppl. 70):S62–S65.
   PubMed Web of Science ®Google Scholar
• Puéchal X, Rivereau P, Vinchon F. Churg-Strauss syndrome associated with omalizumab. J Int Med. 2008;19(5):364–366.
   Web of Science ®Google Scholar
• Jachiet M, Samson M, Cottin V, et al. Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheum. 2016;68(9):2274–2282.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Wong DA, Miller MK, et al. Churg-Strauss syndrome in patients treated with omalizumab. Chest. 2009;136(2):507–518.
   PubMed Web of Science ®Google Scholar
• Detoraki A, Di Capua L, Varricchi G, et al. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. J Asthma. 2016;53(2):201–206.
   PubMed Web of Science ®Google Scholar
• Park JW, Curtis JR, Moon J. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high dose glucocorticoids. Ann Rheum Dis. 2018;77(5):644–649.
   PubMed Web of Science ®Google Scholar
• Sokolowska B, Szczeklik W, Wludarczyk A, et al. ANCA-positive and anca-negative phenotypes of eosinophilic granulomatosis with polyangiitis (egpa): outcome and long-term follow-up of 50 patients from a single Polish centre. Clin Exp Rheumatol. 2014;32(3 Suppl. 82):S41–S47.
   PubMed Web of Science ®Google Scholar
• Healy B, Bibby S, Steele R, et al. Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome. J Allergy Clin Immunol. 2013;131(2):571–576.
   PubMed Web of Science ®Google Scholar